0001209191-20-013620.txt : 20200227 0001209191-20-013620.hdr.sgml : 20200227 20200227210009 ACCESSION NUMBER: 0001209191-20-013620 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190225 FILED AS OF DATE: 20200227 DATE AS OF CHANGE: 20200227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doyle Noah CENTRAL INDEX KEY: 0001631673 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37428 FILM NUMBER: 20665250 MAIL ADDRESS: STREET 1: C/O RITTER PHARMACEUTICALS INC. STREET 2: 1801 CENTURY PARK EAST, SUITE 1820 CITY: LOS ANGELES STATE: CA ZIP: 90096 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RITTER PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001460702 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263474527 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1880 CENTURY PARK EAST, SUITE 1000 CITY: LOS ANGELES STATE: CA ZIP: 90067 BUSINESS PHONE: 310-203-1000 MAIL ADDRESS: STREET 1: 1880 CENTURY PARK EAST, SUITE 1000 CITY: LOS ANGELES STATE: CA ZIP: 90067 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-25 0 0001460702 RITTER PHARMACEUTICALS INC RTTR 0001631673 Doyle Noah RITTER PHARMACEUTICALS, INC. 1880 CENTURY PARK EAST, SUITE 1000 LOS ANGELES CA 90067 1 0 0 0 Common Stock 2020-02-25 4 M 0 500000 0.15 A 1204780 I By Javelin Partners, L.P. Common Stock 32275 I By Javelin Venture Partners I SPV I, LLC Common Stock 2272 D Warrants (right to buy) 0.15 2020-02-25 4 M 0 500000 0.00 D 2017-10-03 2022-10-03 Common Stock 500000 0 I By Javelin Partners, L.P. On March 23, 2018, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock (the "Stock Split"). All share numbers and warrant exercise prices in this Form 4 reflect the Stock Split. As the managing director of Javelin Partners, L.P., the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein. As the managing director of Javelin Venture Partners I SPV I, LLC, the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein. As a result of the Stock Split and dilutive issuances of securities after the issuance of the warrants, the exercise price was adjusted to $0.15 per share. /s/ Noah Doyle 2020-02-27